Join Growin Stock Community!

United-guardian, inc.UG.US Overview

US StockConsumer Defensive
(No presentation for UG)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

UG AI Insights

UG Overall Performance

UG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

UG Recent Performance

-2.38%

United-guardian, inc.

-1.34%

Avg of Sector

-0.31%

S&P500

UG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

UG Key Information

UG Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

UG Profile

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.

Price of UG

UG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

UG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.43
PE Ratio (TTM)
14.35
Forward PE
-
PS Ratio (TTM)
3.07
PB Ratio
2.92
Price-to-FCF
19.19
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.60%
Net Margin
19.48%
Revenue Growth (YoY)
-18.29%
Profit Growth (YoY)
-22.62%
3-Year Revenue Growth
-2.15%
3-Year Profit Growth
-10.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.43
PE Ratio (TTM)
14.35
Forward PE
-
PS Ratio (TTM)
3.07
PB Ratio
2.92
Price-to-FCF
19.19
Gross Margin
50.60%
Net Margin
19.48%
Revenue Growth (YoY)
-18.29%
Profit Growth (YoY)
-22.62%
3-Year Revenue Growth
-2.15%
3-Year Profit Growth
-10.76%

  • When is UG's latest earnings report released?

    The most recent financial report for United-guardian, inc. (UG) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating UG's short-term business performance and financial health. For the latest updates on UG's earnings releases, visit this page regularly.

  • Where does UG fall in the P/E River chart?

    According to historical valuation range analysis, United-guardian, inc. (UG)'s current price-to-earnings (P/E) ratio is 15.38, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of UG?

    According to the latest financial report, United-guardian, inc. (UG) reported an Operating Profit of 215.07K with an Operating Margin of 9.5% this period, representing a decline of 77.34% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is UG's revenue growth?

    In the latest financial report, United-guardian, inc. (UG) announced revenue of 2.26M, with a Year-Over-Year growth rate of -26.01%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does UG have?

    At the end of the period, United-guardian, inc. (UG) held Total Cash and Cash Equivalents of 860.84K, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does UG go with three margins increasing?

    In the latest report, United-guardian, inc. (UG) achieved the “three margins increasing” benchmark, with a gross margin of 42.1%%, operating margin of 9.5%%, and net margin of 11.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess UG's profit trajectory and future growth potential.

  • Is UG's EPS continuing to grow?

    According to the past four quarterly reports, United-guardian, inc. (UG)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of UG?

    United-guardian, inc. (UG)'s Free Cash Flow (FCF) for the period is 995.77K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 16.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.